Diacomit is a brand name for the medication stiripentol, which is primarily used in conjunction with other medications to treat seizures associated with Dravet syndrome, a severe form of epilepsy that begins in infancy. Stiripentol works by enhancing the activity of gamma-aminobutyric acid (GABA), a neurotransmitter in the brain that inhibits nerve transmission, thereby reducing the frequency and intensity of seizures. Diacomit is available in capsule and powder form for oral suspension, allowing for flexible dosing tailored to the patient's needs. It is specifically indicated for patients who have not achieved adequate seizure control with other treatments, offering a vital option for managing this challenging condition.